Karyopharm Therapeutics(US:KPTI)2026-02-12 14:00Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $34.1 million, an increase of 11.8% compared to Q4 2024. For the full year, total revenue was $146.1 million, a slight increase from 2024 [26]. - U.S. XPOVIO net product revenue for Q4 2025 was $32.1 million, an increase of 9.6% compared to Q4 2024. For the full year, U.S. XPOVIO net product revenue was $114.9 million, an increase of 1.9% from 2024 [26]. - Gross to net provisions for XPOVIO were 26.9% in Q4 and 31.2% for the full year 2025 [26]. - The company reported a net loss of $102.2 million, or $5.71 per share in Q4 2025, and a net loss of $196 million, or $17.93 per diluted share for the full year 2025 [32]. Business Line Data and Key Metrics Changes - Xpovio net product revenue grew to $32.1 million in Q4 2025 and $114.9 million for the full year 2025, with expectations to deliver revenue growth in 2026, guiding towards $115 million-$130 million [18]. - The community setting continues to drive approximately 60% of total U.S. sales for Xpovio [18]. Market Data and Key Metrics Changes - In the myelofibrosis market, the only treatment options currently available are JAK inhibitors, with ruxolitinib being the standard of care for the past 15 years [21]. - There are approximately 20,000 patients living with myelofibrosis in the U.S., representing a multibillion-dollar marketplace, with about 6,000 newly diagnosed patients each year [22]. Company Strategy and Development Direction - Karyopharm is focusing on expanding its oncology franchise, particularly in myelofibrosis and endometrial cancer, with pivotal data expected in March and mid-2026, respectively [4][5]. - The company aims to establish a new standard of care in frontline myelofibrosis by combining selinexor with ruxolitinib, addressing the unmet need in the market [21][24]. - The strategy includes evaluating a range of financing and strategic options to maintain flexibility and align capital decisions with value creation [5]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts from pivotal trials, which could significantly expand the role of the oncology franchise [35]. - The company is managing its business with a clear focus on near-term value-creating milestones while maintaining flexibility in capital allocation [35]. Other Important Information - Research and development expenses for Q4 2025 were $27.7 million, a decrease of 17% from Q4 2024, driven by lower personnel costs and focused clinical trial expenses [29]. - Selling, general, and administrative expenses were $22.8 million for the quarter, a decrease of 16% compared to Q4 2024 [29]. Q&A Session Summary Question: Can you discuss the differences in exposure and activity between the 40 mg and 60 mg doses? - Management indicated that the 60 mg dose showed a clear benefit-risk profile compared to the 40 mg dose, with maximized efficacy in the 60 mg group [38][39]. Question: What are the implications of Novartis' new plans in myelofibrosis? - Management noted that Novartis' investment in myelofibrosis highlights the unmet need in the market, and Karyopharm aims to establish itself as the standard of care pending positive data [41][44]. Question: What is the strategy for eltanexor and other myeloproliferative neoplasms (MPNs)? - Eltanexor is a second-generation XPO1 inhibitor with potential applications in other MPNs, and the company is excited about expanding beyond myelofibrosis [46][47][48]. Question: Can you provide updates on the blinded safety data and any changes in discontinuation rates? - Management confirmed that no updates have been made beyond previously disclosed data, and they are looking forward to the upcoming data readout [52][55].